Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Issuances (2022 - 2023)

Historic Long-Term Debt Issuances for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Q3 2023 value amounting to $15.0 million.

  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances changed N/A to $15.0 million in Q3 2023 from the same period last year, while for Dec 2024 it was $15.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $15.0 million for FY2023, which is 20000.0% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Long-Term Debt Issuances stood at $15.0 million for Q3 2023.
  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances' 5-year high stood at $15.0 million during Q3 2023, with a 5-year trough of $446000.0 in Q4 2022.